Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation InhibitorsAnnachiara Gandini, María Laura Bolognesi, Josefa Zaldívar-Díez et al.|Journal of Medicinal Chemistry|2018Cited by 104
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatmentLoreto Martínez‐González, Eva de Lago, Carmen Rodríguez‐Cueto et al.|Scientific Reports|2020Cited by 68
Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral SclerosisLoreto Martínez‐González, Ana Martı́nez, Claudia Gonzalo‐Consuegra et al.|International Journal of Molecular Sciences|2021Cited by 67
Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson’s DiseaseRita Maria Concetta Di Martino, Federica Belluti, Letizia Pruccoli et al.|ACS Chemical Neuroscience|2020Cited by 58
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosisElisa Rojas‐Prats, Ana Martı́nez, Loreto Martínez‐González et al.|European Journal of Medicinal Chemistry|2020Cited by 48